Stocks · Healthcare · Medical - Diagnostics & Research
Fulgent Genetics, Inc. FLGT
$21.48 +0.85% Close, Oct 2, 2026 · NASDAQ · Market cap $610.0M
Low risk
Next earnings report: Nov 6, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -37.1% from -24.0% a year earlier.
- The diluted share count fell 9.2% in a year, mainly through buybacks.
- Revenue over the last four quarters was $323.9M, up 6.8% from a year earlier, slowing from 9.5% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 45%
- Revenue growth, 3-year CAGRBottom 8%
- Revenue growth accelerationBottom 33%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 43%
- Gross marginBottom 24%
- Operating marginBottom 37%
- Accruals (lower is better)Bottom 18%
- Interest coverBottom 8%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 41%
- Free-cash-flow yieldBottom 27%
- EBITDA / enterprise valueBottom 38%
- Sales / enterprise valueTop 24%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 27%
- 6-month returnTop 34%
- 1-year return vs S&P 500Bottom 37%
- Distance from 52-week highTop 48%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetBottom 5%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 44%
- Maximum drawdown, 3 yearsTop 29%
- Beta vs S&P 500 (lower is better)Top 14%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 9.5% | 6.8% | ↓ |
| Gross margin | 40.0% | 35.6% | ↓ |
| Operating margin | -24.0% | -37.1% | ↓ |
| FCF margin | -19.8% | -32.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 6.8% | 9.5% | ↓ | Bottom 45% |
| Gross margin | 35.6% | 40.0% | ↓ | Bottom 24% |
| Operating margin | -37.1% | -24.0% | ↓ | Bottom 37% |
| Net margin | -26.0% | -16.8% | ↓ | — |
| Free-cash-flow margin | -32.0% | -19.8% | ↓ | — |
| Return on invested capital | -11.1% | — | Top 43% | |
| Revenue growth, 3-year CAGR | -19.5% | — | Bottom 8% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -0.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 11.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -23.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -504.7×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 10.60%
- Shareholder yield
- 10.60%
- Share count change, 1 year
- -9.2%
- Share count change, 3-year CAGR
- -2.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -1.3%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $19.00
- Target vs current price
- -11.5%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | -26.1% | +2.9% | -5.7% | +0.9% | — |
| May 1, 2026 | -3.4% | -7.0% | -0.5% | +19.4% | +29.2% |
| Feb 27, 2026 | +433.3% | -38.1% | -42.4% | -33.9% | -30.9% |
| Nov 7, 2025 | +158.3% | +18.2% | +32.6% | +24.6% | +14.4% |
| Aug 1, 2025 | +130.4% | +7.9% | +18.8% | +28.2% | +38.2% |
| May 2, 2025 | +121.1% | +19.1% | +7.6% | +20.1% | +1.9% |
| Feb 28, 2025 | +112.9% | -1.5% | +14.1% | +7.4% | +29.4% |
| Nov 8, 2024 | +263.2% | -11.8% | -19.2% | -8.8% | -24.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.58 | -$0.46 | -26.1% | $85.4M |
| May 1, 2026 | -$0.36 | -$0.35 | -3.4% | $71.1M |
| Feb 27, 2026 | $0.16 | $0.03 | +433.3% | $83.3M |
| Nov 7, 2025 | $0.14 | -$0.24 | +158.3% | $84.1M |
| Aug 1, 2025 | $0.07 | -$0.23 | +130.4% | $81.8M |
| May 2, 2025 | $0.04 | -$0.19 | +121.1% | $73.5M |
| Feb 28, 2025 | $0.04 | -$0.31 | +112.9% | $76.2M |
| Nov 8, 2024 | $0.31 | -$0.19 | +263.2% | $71.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 1.83× | — | — | Top 24% |
| Free-cash-flow yield | -17.01% | — | — | Bottom 27% |
| Earnings yield | -13.13% | — | — | Bottom 41% |
P/E over the past five years
Range 3.7× – 7.2× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 20
- Days above the 200-day average
- 15
- 50-day average slope (20 days)
- +1.7%
- 200-day average slope (20 days)
- -3.5%
- Distance from 50-day average
- +7.3%
- Distance from 200-day average
- +7.4%
- RSI (14)
- 55.7
- Relative volume
- 0.90×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 52.6%
- Volatility vs own 5-year history
- 69th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.47
- Correlation with S&P 500
- 0.13
- Current drawdown from 1-year high
- -30.4%
- Maximum drawdown, 3 years
- -55.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 9, 2021 | Mar 3, 2026 | -92.5% | 1270 days | Not yet recovered |
| Oct 5, 2020 | Nov 9, 2020 | -34.0% | 25 days | 16 days (Dec 2, 2020) |
| Feb 1, 2021 | Feb 2, 2021 | -18.2% | 1 days | 3 days (Feb 5, 2021) |
| Dec 10, 2020 | Dec 16, 2020 | -15.1% | 4 days | 10 days (Dec 31, 2020) |
| Jan 19, 2021 | Jan 21, 2021 | -13.7% | 2 days | 4 days (Jan 27, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $610.0M
- EPS, diluted (TTM)
- -$2.82
- Revenue (TTM)
- $323.9M
- 52-week range
- $13.46 – $31.04
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $992.6M | $619.0M | $289.2M | $283.5M | $322.7M |
| Gross profit | $777.1M | $366.9M | $104.5M | $107.2M | $130.9M |
| Operating income | $676.0M | $178.5M | -$195.5M | -$73.9M | -$91.1M |
| Net income | $507.4M | $143.4M | -$167.8M | -$42.7M | -$60.5M |
| EPS (diluted) | $16.26 | $4.63 | -$5.63 | -$1.41 | -$1.97 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.7M | $76.2M | $73.5M | $81.8M | $84.1M | $83.3M | $71.1M | $85.4M |
| Net income | -$14.6M | -$5.9M | -$11.5M | -$19.0M | -$6.6M | -$23.4M | -$24.8M | -$29.5M |
| EPS (diluted) | -$0.48 | -$0.19 | -$0.37 | -$0.61 | -$0.21 | -$0.76 | -$0.80 | -$1.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $538.6M | $253.5M | $27.0M | $21.1M | -$101.6M |
| Capital expenditure | -$23.8M | -$18.8M | -$22.2M | -$40.3M | -$22.6M |
| Free cash flow | $514.7M | $234.7M | $4.8M | -$19.3M | -$124.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $85.3M | -$76.1M | -$27.8M | -$3.1M | -$13.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $257.0M
- Total assets
- $1.09B
- Total liabilities
- $93.2M
- Total debt
- $9.4M
- Net debt
- -$16.9M
- Shareholders’ equity
- $1.00B
As of Jun 30, 2026 (filed Jul 30, 2026).
Short interest
- Shares sold short
- 2,318,058
- Days to cover
- 6.71
- Change vs previous report
- -2.1%
FINRA short interest, settlement date Sep 15, 2026.